2. Search Result
Search Result
Results for "

myocardium

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-13948
    Angiotensin II human
    Maximum Cited Publications
    222 Publications Verification

    Angiotensin II; Ang II; DRVYIHPF

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human
  • HY-13948A
    Angiotensin II human acetate
    Maximum Cited Publications
    222 Publications Verification

    Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human acetate
  • HY-103160A
    EHNA hydrochloride
    5 Publications Verification

    		 Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA hydrochloride is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA hydrochloride
  • HY-17436
    Clevidipine

    		Calcium Channel Cardiovascular Disease Cancer
    Clevidipine is a selective, short-acting L-type calcium channel antagonist with an IC50 of 7.1 nM. Clevidipine can competitively bind to calcium channels and exert rapid vasoselective vasodilation by blocking the influx of extracellular calcium ions, thereby reducing peripheral vascular resistance and effectively controlling acute severe hypertension. Clevidipine can also protect the myocardium from reperfusion injury by promoting the release of nitric oxide (NO). Clevidipine can be used in the research of acute hypertension, perioperative blood pressure management, and myocardial ischemia-reperfusion injury .
    Clevidipine
  • HY-13948B
    Angiotensin II human TFA
    Maximum Cited Publications
    222 Publications Verification

    Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human TFA
  • HY-103346
    MMPSI

    		Caspase Apoptosis Cardiovascular Disease
    MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC50 of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection .
    MMPSI
  • HY-W704966
    2-Stearoyl-sn-glycero-3-phosphocholine

    		Endogenous Metabolite Metabolic Disease
    2-Stearoyl-sn-glycero-3-PC is a lysophospholipid that contains stearic acid (HY-B2219) at the sn-2 position. It has been found in rabbit myocardium.
    2-Stearoyl-sn-glycero-3-phosphocholine
  • HY-P5792
    Atrial natriuretic peptide (3-28) (human)

    ANP (3-28) (human)

    		 Endothelin Receptor Cardiovascular Disease Metabolic Disease
    Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)) is a peptide hormone that is synthesized and secreted by the atrial myocardium. Atrial natriuretic peptide (3-28) (human) is involved in the regulation of blood pressure, fluid balance, and electrolyte homeostasis .
    Atrial natriuretic peptide (3-28) (human)
  • HY-W276164
    Sodium octadecyl sulfate

    Sodium stearyl sulfate

    		 Biochemical Assay Reagents Others
    Sodium octadecyl sulfate (Sodium stearyl sulfate) is a long-chain alkyl sodium sulfate that functions as an emulsifier, crosslinking agent, and regulator. Sodium octadecyl sulfate has high safety, with a LD50 greater than 3.00 Gm./Kg for both intraperitoneal injection in mice and oral administration in rats. Sodium octadecyl sulfate enhances continuous contraction of the gastrocnemius muscle in frogs and boosts intestinal smooth muscle activity in albino rats. However, Sodium octadecyl sulfate exerts no significant effect on isolated tortoise myocardium and does not alter the conduction function of frog sciatic nerves. Sodium octadecyl sulfate can also be used to coat the surface of starch aggregates, promote crosslinking and increase aggregate size through hydrophobic and electrostatic interactions, and further form a coexistent B-V type crystalline structure with acid-hydrolyzed gelatinized starch, thereby effectively modifying the structure and surface properties of high-starch systems .
    Sodium octadecyl sulfate
  • HY-19463A
    F15845

    		Sodium Channel Cardiovascular Disease
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment .
    F15845
  • HY-19463
    F-15845 hydrobromide

    		Sodium Channel Cardiovascular Disease
    F 15845 hydrobromide is a highly effective persistent sodium current blocker. F 15845 hydrobromide is also a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 hydrobromide can be used for the research of myocardium functional impairment .
    F-15845 hydrobromide
  • HY-N3931
    Gardneramine

    		Others Cardiovascular Disease
    Gardneramine is an orally active alkaloid that acts like papaverine. Gardneramine has peripheral vascular diastolic effect, direct inhibition on myocardium and central inhibition. Gardneramine showed antihypertensive, vasodilatation and atrial inhibition effects in rabbit, dog and guinea pig models, respectively. Gardneramine also inhibits the movement of smooth muscle organs such as the stomach and intestines .
    Gardneramine
  • HY-106844
    EMD 53998

    		Phosphodiesterase (PDE) Cardiovascular Disease
    EMD 53998 is a cardiotonic agent that increases myocardial contractility as an inhibitor for phosphodiesterase III (PDE III) and a calcium sensitizer. EMD 53998 increases myocardial contractility, reduces energy consumption and the risk of inducing arrhythmias .
    EMD 53998
  • HY-103160B
    EHNA

    		Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA
  • HY-116119
    BDF 9148

    		Sodium Channel Cardiovascular Disease
    BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure .
    BDF 9148
  • HY-117055
    Ro 18-3981

    		Calcium Channel Cardiovascular Disease
    Ro 18-3981 is a dihydropyridine that inhibits cardiac Ca 2+ channels. Ro 18-3981 shows higher inhibitory activity when the cell membrane is in a depolarized state (Vh=-20 mV: IC50=2.3 nM; Vh=-50 mV: IC50=100 nM) .
    Ro 18-3981
  • HY-W184837
    m-Nisoldipine

    KR-1008

    		 Calcium Channel Cardiovascular Disease
    m-Nisoldipine (KR-1008) is a dihydropyridine calcium antagonist that can significantly increase cardiac output and heart index, significantly reduce the negative inotropic effect on the myocardium, and has a relatively high selectivity for the thoracic aorta. m-Nisoldipine can be used in the research of cardiovascular diseases .
    m-Nisoldipine
  • HY-123721
    Tiracizine hydrochloride

    AWD-19-166; GS 015

    		 Endogenous Metabolite Cardiovascular Disease
    Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease .
    Tiracizine hydrochloride
  • HY-125144
    BIIB 513

    		Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BIIB 513 is an inhibitor of NHE 1 that protects against myocardial ischemia. BIIB 513 inhibits acid load recovery with an IC50 of 27 nmol/L in cells expressing wild-type NHE 1 under acute acid load .
    BIIB 513
  • HY-14257
    BMS-191095 hydrochloride

    		Potassium Channel Lactate Dehydrogenase Cardiovascular Disease
    BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects .
    BMS-191095 hydrochloride
  • HY-105269A
    Org 30029 hydrochloride

    		Calcium Channel Cardiovascular Disease
    Org 30029 hydrochloride is a Ca 2+ sensitizer with positive inotropic effect. Org 30029 hydrochloride can be used for the research of cardiovascular disease .
    Org 30029 hydrochloride
  • HY-117135
    HNS-32

    		Sodium Channel Calcium Channel PKC Cardiovascular Disease
    HNS-32 is a compound with antiarrhythmic and vasodilatory effects in canine hearts, showing superior protective effects against ischemic and reperfusion arrhythmias compared to an equivalent dose of Mexiletine hydrochloride (HY-A0093). Furthermore, HNS-32 exhibits significant negative chronotropic effects on mammalian ventricular myocardium, indicating its potential application value in the study of acute coronary syndrome .
    HNS-32
  • HY-N0272R
    Eleutheroside E (Standard)

    		Reference Standards Others Inflammation/Immunology
    Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis .
    Eleutheroside E (Standard)
  • HY-103346R
    MMPSI (Standard)

    		Reference Standards Caspase Apoptosis Cardiovascular Disease
    MMPSI (Standard) is the analytical standard of MMPSI (HY-103346). This product is intended for research and analytical applications. MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC50 of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection .
    MMPSI (Standard)
  • HY-180344
    Flurpiridaz

    		Biochemical Assay Reagents Cardiovascular Disease
    Flurpiridaz is a positron emission tomography (PET) myocardial perfusion imaging tracer. Flurpiridaz can bind to mitochondrial complex I with high affinity. Flurpiridaz demonstrates high heart uptake in multiple species with clear delineation of perfusion deficits. Flurpiridaz shows rapid uptake in the myocardium. Flurpiridaz can be studied in research on coronary artery disease .
    Flurpiridaz
  • HY-B1562D
    (S)-Bopindolol

    		Adrenergic Receptor Metabolic Disease
    (S)-Bopindolol is a β-adrenergic receptor blocker that can be used to prevent, inhibit, can be used to reduce muscle mass and/or functional loss and/or decreased bone density caused by weight loss. (S)-Bopindolol can protect the myocardium and/or cardiac function, or prevent low blood pressure and/or increased heart rate during weight loss .
    (S)-Bopindolol
  • HY-P11741
    BV2

    		Exosomes Biochemical Assay Reagents Neurological Disease
    BV2 is a delivery peptide that binds to BVES, with a Ka of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy .
    BV2
  • HY-103160AR
    EHNA hydrochloride (Standard)

    		Reference Standards Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA hydrochloride (Standard) is the analytical standard of EHNA hydrochloride (HY-103160A). This product is intended for research and analytical applications. EHNA hydrochloride is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA hydrochloride (Standard)
  • HY-165397
    NA 0345

    		PKC Cardiovascular Disease
    NA 0345 is a PKC inhibitor with IC50 values of 70 nM and 110 nM in the presence and absence of 12-O-tetradecanoyl-13-acetate, respectively. NA 0345 inhibits PKC and selectively suppresses the positive inotropic effect mediated by α1-adrenergic receptors .
    NA 0345
  • HY-175991S
    Sodium octadecyl sulfate-d37

    Sodium stearyl sulfate sulfate-d37

    		 Isotope-Labeled Compounds Biochemical Assay Reagents Others
    Sodium octadecyl sulfate-d37 (Sodium stearyl sulfate-d37) is the deuterium labeled Sodium octadecyl sulfate (HY-W276164). Sodium octadecyl sulfate (Sodium stearyl sulfate) is a long-chain alkyl sodium sulfate that functions as an emulsifier, crosslinking agent, and regulator. Sodium octadecyl sulfate has high safety, with a LD50 greater than 3.00 Gm./Kg for both intraperitoneal injection in mice and oral administration in rats. Sodium octadecyl sulfate enhances continuous contraction of the gastrocnemius muscle in frogs and boosts intestinal smooth muscle activity in albino rats. However, Sodium octadecyl sulfate exerts no significant effect on isolated tortoise myocardium and does not alter the conduction function of frog sciatic nerves. Sodium octadecyl sulfate can also be used to coat the surface of starch aggregates, promote crosslinking and increase aggregate size through hydrophobic and electrostatic interactions, and further form a coexistent B-V type crystalline structure with acid-hydrolyzed gelatinized starch, thereby effectively modifying the structure and surface properties of high-starch systems .
    Sodium octadecyl sulfate-d37

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: